Early death and CSF monoamine metabolites in schizophrenia spectrum psychosis

Nordic Journal of Psychiatry

Volumn 65, Issue 2, 2011, Pages 101-105

  Carlborg, Andreas ^a   Jokinen, Jussi ^a   Nordström, Anna Lena ^a   Jönsson, Erik G ^a   Nordström, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CSF monoamine metabolites; Early death; Mortality; Psychosis; Schizophrenia

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; HOMOVANILLIC ACID; MONOAMINE DERIVATIVE;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SUICIDE ATTEMPT;

ADULT; AGE FACTORS; CAUSE OF DEATH; CEREBROSPINAL FLUID; FEMALE; FOLLOW-UP STUDIES; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SWEDEN; YOUNG ADULT;

EID: 79952654913     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2010.503903     Document Type: Article

References (36)

1. Allebeck P, Varla A, Wistedt B. Suicide and violent death among patients with schizophrenia. Acta Psychiatr Scand 1986;74:43-9. (Pubitemid 16061286)
2. Auquier P, Lancon C, Rouillon F, Lader M. Mortality in schizo-phrenia. Pharmacoepidemiol Drug Saf 2007;16:1308-12.
3. Brown S. Excess mortality of schizophrenia. A meta-analysis. J Clin Psychiatry 1997;171:502-8. (Pubitemid 27527317)
4. Ö sby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-8.
5. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiat-ric disorders: A register-based study comparing mortality in uni-polar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 2007;68:899-907. (Pubitemid 47015490)
6. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31. (Pubitemid 47529346)
7. Faustman WO, Ringo DL, Faull KF. An association between low levels of 5-HIAA and H VA in cerebrospinal fluid and early mor-tality in a diagnostically mixed psychiatric sample. Br J Psychia-try 1993;163:519-21. (Pubitemid 23297471)
8. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy life-style of people with schizophrenia. Psychol Med 1999;29: 697-701.
9. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler L P, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-20. (Pubitemid 29193917)
10. Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003;4:819-28. (Pubitemid 37314404)
11. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999;156:181-9. (Pubitemid 29077107)
12. Brown GL, Linnoila MI. CSF serotonin metabolite (5-HIAA) stud-ies in depression, impulsivity, and violence. J Clin Psychiatry 1990;51 Suppl:31-41; discussion 42-3. (Pubitemid 20134805)
13. Lidberg L, Belfrage H, Bertilsson L, Evenden MM, Asberg M. Sui-cide attempts and impulse control disorder are related to low cer-ebrospinal fluid 5-HIAA in mentally disordered violent offenders. Acta Psychiatr Scand 2000;101:395-402. (Pubitemid 30233006)
14. Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ. Aggressivity, suicide attempts, and depression: Relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry 2001;50:783-91. (Pubitemid 33086766)
15. Stanley B, Molcho A, Stanley M, Winchel R, Gameroff MJ, Parsons B, et al. Association of aggressive behavior with altered serotonergic function in patients who are not suicidal. Am J Psychiatry 2000;157:609-14. (Pubitemid 30191201)
16. Currier D, Mann JJ. Stress, genes and the biology of suicidal behavior. Psychiatr Clin North Am 2008;31:247-69. (Pubitemid 351551422)
17. Carlborg A, Jokinen J, Nordström AL, Jönsson EG, Nordström P. CSF 5-HIAA, attempted suicide and suicide risk in schizophrenia spectrum psychosis. Schizophr Res 2009;112:80-5.
18. Carlborg A, Jokinen J, Nordström AL, Jönsson EG, Nordström P. Attempted suicide predicts suicide risk in schizophrenia spectrum psychosis. Nord J Psychiatry 2009;64:68-72.
19. Carlborg A, Jokinen J, Jönsson EG, Nordström AL, Nordström P. Long-term suicide risk in schizophrenia spectrum psychoses: Sur-vival analysis by gender. Arch Suicide Res 2008;12:347-51.
20. Bjerkenstedt L, Gullberg B, H ä rnryd C, Sedvall G. Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene. Arch Psychiatr Nervenkr 1977;224:107-18. (Pubitemid 8192454)
21. H ä rnryd C, Bjerkenstedt L, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand Suppl 1984;311:75-92.
22. Oxenstierna G, Bergstrand G, Edman G, Flyckt L, Nyb ä ck H, Sed-vall G. Increased frequency of aberrant CSF circulation in schizo-phrenic patients compared to healthy volunteers. Eur Psychiatry 1996;11:16-20. (Pubitemid 26069830)
23. Wode-Helgodt B, Fyr ö B, Gullberg B, Sedvall G. Effect of chlo-rpromazine treatment on monoamine metabolite levels in cerebros-pinal fluid of psychotic patients. Acta Psychiatr Scand 1977;56:129-42. (Pubitemid 8160021)
24. Sedvall GC, Wode-Helgodt B. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients. Arch Gen Psychiatry 1980;37:1113-16. (Pubitemid 10015014)
25. Swahn CG, Sandgarde B, Wiesel FA, Sedvall G. Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method. Psy-chopharmacology (Berl) 1976;48:147-53.
26. National Strategy for Suicide Prevention. Goals and Objectives for Action. Rockville, MD: US Department of Health and Human Serv-ices, Public Health Service; 2001.
27. Ekholm B, Ekholm A, Adolfsson R, Vares M, Ö sby U, Sedvall GC, et al. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord J Psychiatry 2005;59:457-64. (Pubitemid 41801793)
28. Vares M, Ekholm A, Sedvall GC, Hall H, J ö nsson EG. Characteri-zation of patients with schizophrenia and related psychoses: Evalua-tion of different diagnostic procedures. Psychopathology 2006;39:286-95. (Pubitemid 44492194)
29. Pompili M, Amador X F, Girardi P, Harkavy-Friedman J, Harrow M, Kaplan K, et al. Suicide risk in schizophrenia: Learning from the past to change the future. Ann Gen Psychiatry 2007;6:10.
30. Mortensen PB, Juel K. Mortality and causes of death in first admit-ted schizophrenic patients. Br J Psychiatry 1993;163:183-9. (Pubitemid 23233086)
31. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4-14.
32. Glassman AH. Depression and cardiovascular comorbidity. Dia-logues Clin Neurosci 2007;9:9-17. (Pubitemid 46607127)
33. Hansen V, Jacobsen BK, Arnesen E. Cause-specific mortality in psychiatric patients after deinstitutionalisation. Br J Psychiatry 2001;179:438-43. (Pubitemid 33097167)
34. Seeman M V. An outcome measure in schizophrenia: Mortality. Can J Psychiatry 2007;52:55-60. (Pubitemid 46743498)
35. Statistics S. Mean life expectancy for general population 50 years of age 2003-2007. Statistics Sweden 2009.
36. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: A review of the literature. Acta Psychiatr Scand 2007;116:317-33. (Pubitemid 47537428)